

Foreword

Rarely before has the field of nuclear medicine grown at such a pace as today. Reimbursement in many countries has led to a growing acceptance of PET and now PET-CT in the clinical setting and its full integration into clinical practice. At the same time, many new and promising target-specific radioligands have emerged in the research laboratory and await translation into the clinical environment. Once introduced into the clinic, they are likely to further transform the scope of nuclear medicine with substantial implications for patient care, including patient diagnosis and staging of disease and risk assessment. Moreover, they are likely to enhance treatment response monitoring and, importantly, facilitate tailoring of patient-specific treatment strategies.

Advances in imaging instrumentation have further accelerated the pace of growth in clinical nuclear medicine. Greater sensitivity together with higher spatial and temporal resolution capabilities has shortened clinical imaging times and thus increased patient throughput. It has also enhanced our ability to visualize and quantify normal functional processes, or altered, even when still subtle in magnitude in developing disease or when still confined to anatomically small regions. Importantly, PET-CT allows accurate localization of functional processes including rates of metabolism, receptor expression and activity, cell-cell or cell-tissue interactions, or events occurring at the molecular level. Functional parameters can thus be assigned to disease-related structural derangements. Finally, research in molecular imaging continues to produce a stream of novel, target-specific radioligands for probing molecular and cellular processes and promising to visualize and delineate cellular and molecular events at the onset of disease or in response to therapy. Many of these novel probes hold considerable promise for defining new targets for therapeutic strategies or, conversely, to serve as therapeutic agents themselves.

These impressive advances offer new and exciting opportunities for broadening the practice of nuclear medicine. Yet they also pose tremendous challenges to the clinician, especially as to how best apply the ever-growing array of imaging capabilities to patient care. The editors, Doctors Schober and Heindel deserve credit for providing us with a comprehensive and concisely written survey of the current state of clinical PET and PET-CT imaging. They have enlisted an outstanding team of contributors, all active clinicians in nuclear medicine, radiology, oncology, radiation therapy, neurology, or cardiology. As most of the contributors practice at the same academic medical center, they present a unified and coordinated approach to diagnostic imaging.

The text covers the full range of current PET and PET-CT applications, including those in neurology and cardiology and appropriately emphasizes applications in oncology. Importantly, the chapters adhere to a consistent structure and include a brief assessment of alternative imaging approaches such as MRI and CT, listing advantages and limitations, a feature which is especially useful for selecting the most effective and appropriate imaging approach and deciding when to use PET or PET-CT for solving a clinical question. I wish to congratulate the editors and contributors alike on this superb book, which serves as a readily accessible resource to the imaging clinician and as a well-organized, easily readable, and well-illustrated introduction to PET-CT for the beginner.

Heinrich R. Schelbert
George V. Taplin Professor
David Geffen School of Medicine at UCLA
University of California at Los Angeles
Los Angeles, CA, USA

Malignant Pleural Mesothelioma

Introduction and Staging

Malignant pleural mesothelioma (MPM) accounts for less than 2% of all thoracic tumors but is the most common pleural malignancy. The likelihood of contracting this disease is increased approx. 100-fold by asbestos exposure (Sohrab and Konietzko 2002). Generally a period of 20–30 years elapses between the initial asbestos exposure and manifestation of disease. In many countries the manufacture and processing of asbestos has been prohibited since the early 1990s, so it is reasonable to predict that the incidence of MPM will peak around the year 2020. By the year 2030 it is estimated that MPM will have caused approx. 250 000 deaths in Western Europe (Sohrab and Konietzko 2002). MPM has a very poor prognosis with a median survival time of 4–18 months. The average 5-year survival rate is no more than 2.5% (Bonomo et al. 2000).

MPM typically spreads within the pleural cavity. Accordingly, a hemorrhagic effusion is almost invariably present. It is also common for MPM to invade the chest wall, diaphragm, or mediastinum. Because MPM usually arises from cells of the parietal pleura, the pattern of nodal metastasis differs from that of parenchymal lung tumors. Initial nodal metastasis is usually to lymph nodes that drain the parietal pleura (TNM stage N2). Distant metastases are rare. The staging of MPM is based on the TNM classification (Rusch 1996).

The three histologic types of MPM are described as epithelial, mesenchymal, and mixed. The differentiated epithelial type is the most common and has, relatively, the best prognosis (Sugarbaker et al. 1999).

Imaging Studies

CT

Typical findings. Typical morphologic features of MPM on CT scans are complete encasement of the lung or multiple sites of nodular pleural thickening with involvement of the interlobar septa. The tumor usually shows intense, inhomogeneous enhancement after intravenous contrast administration. Additionally, a pleural effusion is usually present, and pericardial effusion may develop in advanced cases. Often these signs are absent in the early stage, making it initially impossible to distinguish between a benign and a malignant pleural process on the basis of CT findings (Benamore et al. 2005).

Staging. CT is the dominant imaging modality for the preoperative staging of MPM and supplies information that is essential for this purpose. Chest-wall invasion,

pulmonary involvement (by lymphatic or hematogenous dissemination of tumor cells), and involvement of the pericardium and mediastinal lymph nodes can be adequately evaluated by CT. As with lung cancer, unequivocal CT signs of chest-wall or mediastinal invasion are bone destruction and/or invasion of the intercostal muscles. The obliteration of extrapleural fat planes is another manifestation of chest-wall involvement (Benamore et al. 2005). In one study, morphologic CT criteria were applied in 34 patients with MPM to correctly exclude chest-wall invasion in 93%, diaphragmatic invasion in 94%, and mediastinal invasion in 100% of the cases. The extent of chest-wall and diaphragmatic involvement was underestimated by CT, however (Patz et al. 1992).

FDG PET

Malignant pleural mesotheliomas show increased FDG uptake. Twenty-eight patients were evaluated by FDG PET imaging (Bénard et al. 1998). When a SUV cutoff of 2 was used, a sensitivity of 91% and a specificity of 100% were achieved in differentiating between malignant and benign pleural lesions. Epithelial MPM showed lower FDG uptake on average than the other types. The survival times of the seven patients who died from MPM showed a significant correlation with the mean SUV of the tumor (Bénard et al. 1999).

Other studies have also documented the contribution of FDG PET to the evaluation of pleural lesions (Carretta et al. 2000; Schneider et al. 2000). As in the case of CT, however, it is difficult to distinguish between MPM and a pleural metastasis from a nonpleural primary tumor (Carretta et al. 2000). It is essential, therefore, that the diagnosis be confirmed by biopsy before any treatment is initiated. Furthermore, FDG PET cannot provide accurate anatomic localization of increased uptake, making it unsuitable for T staging. In summary, the importance of FDG PET in the diagnosis and follow-up of MPM has not yet been fully established.

PET-CT

Available data on the utility of PET-CT in MPM are still inconclusive. Twenty-nine patients with MPM who were initially judged to be candidates for extrapulmonary pneumonectomy were evaluated by CT and FDG PET. In 11 of the patients the imaging results negated the indication for pneumonectomy. In 21 of the 29 patients the tumor was correctly staged by PET-CT (Erasmus et al. 2005). In another study, PET-CT was more accurate than PET and CT separately in establishing an indication for extrapulmonary pneumonectomy (Steinert et al. 2005).

PET-CT also provides useful information for evaluating lymph node status. Nodal status was correctly determined in 6 of 17 patients by PET-CT (Erasmus et al. 2005; Fig. 2.30).

FDG PET is not useful for the T staging of MPM.

The utility of PET-CT in MPM is still uncertain.

In the early stage of MPM, it is often impossible to judge on the basis of CT whether the lesion is benign or malignant.






Fig. 2.30 a–g Malignant pleural mesothelioma of the right hemithorax in a 63-year-old man.

a FDG PET (MIP).

b–e PET-CT (**c, e**) with corresponding unenhanced low-dose CT scans (**b, d**). Nodular foci of pleural thickening show a combination of low FDG uptake (**c**, white arrow) and higher uptake (**c**, black arrow; **e**, white arrow). PET-CT is more accurate in determining the exact location of a hypermetabolic lesion for percutaneous biopsy. Enlarged mediastinal lymph node with a fatty hilum (**c**, gray arrow). Absence of FDG uptake indicates an inflammatory-reactive pathogenesis.

f, g Coronal reformations of FDG PET (**f**) and PET-CT (**g**). Accurate image fusion is technically difficult for lesions near the diaphragm (**g**, black and white arrows) but is easy for lesions distant from the diaphragm (**g**, gray arrow).



Continued →




Fig. 2.30 a–g Continued (see legend on p. 115)

To date there have been no systematic studies on the accuracy of PET-CT for TNM staging compared with CT or FDG PET alone.

The combination of anatomic (CT) and metabolic (PET) information can also improve the accuracy of percutaneous biopsy (Fig. 2.30). This has clinical relevance because the cytologic evaluation of a pleural effusion or the histologic examination of a suspect lesion does not always yield definitive results, creating a need for multiple biopsies that may cause iatrogenic tumor cell dissemination (Boutin et al. 1995).

The respiratory movements of the diaphragm mean that there is a natural limit on the detection of diaphragmatic invasion by PET-CT. Early tumor involvement may be completely obscured by respiratory motion. In addition, variations in respiratory excursions may hamper the coregistration of FDG PET and CT images (Fig. 2.30).

Pulmonary Metastases

The lung is the most frequent target site for hematogenous metastasis from extrapulmonary malignancies. The tumors that most commonly metastasize to the lung are carcinomas of the thyroid gland, breast, and prostate, bone and soft-tissue sarcomas, and tumors of the testes, kidneys, adrenal glands, uterus, ovaries, and nasopharynx. Metastases account for the highest percentage of malignant pulmonary nodules.

CT

CT is the modality of choice for diagnosing pulmonary metastases, although lesions less than 6 mm in diameter are notoriously difficult to detect. A study on the detection of histologically confirmed pulmonary metastases by CT indicated an overall sensitivity of 77% for lesions of all sizes. The sensitivity was 94% for metastases 6–10 mm in size but 100% for metastases larger than 10 mm (Diederich et al. 1999).

Moreover, CT cannot positively distinguish between metastases and pulmonary nodules due to other causes. The size of a pulmonary nodule is of only limited value for determining whether or not it is malignant. The same is true of other morphologic parameters (Diederich et al. 2005). The pulmonary nodules detected by CT are frequently benign, even in patients with a known neoplastic disease (Kronawitter et al. 1999; Picci et al. 2001).

The accuracy of CT for identifying malignancy of a lesion can be increased by conducting follow-ups (analyzing changes over time) or by using CT with complementary modalities such as FDG PET.

FDG PET

The ability of FDG PET to detect pulmonary metastases has not yet been investigated for all primary tumor types. Nevertheless, studies to date indicate that FDG PET can detect pulmonary metastases from numerous primary extrapulmonary malignancies such as colon and breast cancer, malignant melanoma, and soft-tissue sarcomas

Even CT may fail to detect a diaphragmatic tumor, because of the respiratory movements of the diaphragm.

- Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. *Radiology* 1997;202(2):441–446
- Steinert HC, Santos Dellea MM, Burger C, Stahel R. Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. *Lung Cancer* 2005;49(Suppl 1):S33–S35
- Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. *Eur J Nucl Med* 1996;23(10):1409–1415
- Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. *J Thorac Cardiovasc Surg* 1999;117(1):54–63, discussion 63–65
- Swensen SJ, Brown LR, Colby TV, Weaver AL, Midthun DE. Lung nodule enhancement at CT: prospective findings. *Radiology* 1996;201(2):447–455
- Thomas M. Therapy of bronchial carcinoma: interdisciplinary and with expertise [in German]. *Pneumologie* 2002;56(2):90–93
- Tolosa EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. *Chest* 2003; 123(1 Suppl):1375–1465
- Truong MT, Erasmus JJ, Macapinlac HA, et al. Integrated positron emission tomography/computed tomography in patients with non-small cell lung cancer: normal variants and pitfalls. *J Comput Assist Tomogr* 2005;29(2):205–209
- Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. *Lancet Oncol* 2003;4(1):45–55
- Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. *J Clin Oncol* 1998;16(6):2142–2149
- Verschakelen JA, Bogaert J, De Wever W. Computed tomography in staging for lung cancer. *Eur Respir J Suppl* 2002;35:40s–48s
- Virgo KS, McKirgan LW, Caputo MC, et al. Post-treatment management options for patients with lung cancer. *Ann Surg* 1995;222(6):700–710
- von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. *Radiology* 2006;238(2):405–422
- Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. *Radiology* 1991;178(3):705–713
- Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. *Ann Thorac Surg* 1998;66(3):886–892, discussion 892–893
- Wormanns D, Diederich S. Characterization of small pulmonary nodules by CT. *Eur Radiol* 2004;14(8):1380–1391
- Wormanns D, Klotz E, Kohl G, et al. Enhancement measurement of pulmonary nodules with multirow detector CT: precision assessment of a 3D algorithm compared to standard procedure. *Proc SPIE* 2003;5032:795–801
- Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. *Thorax* 2006;61(7):597–603
- Yasufuku K, Fujisawa T. Staging and diagnosis of non-small cell lung cancer: invasive modalities. *Respirology* 2007;12(2):173–183
- Yi CA, Lee KS, Kim BT, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. *J Nucl Med* 2006;47(3):443–450

B. Riemann
K. U. Juergens

Tumors of the Upper Digestive Tract

Esophageal Carcinoma

Most esophageal malignancies are diagnosed between 50 and 60 years of age, with males predominating in a 4:1 ratio. The physiologic constrictions of the esophagus are sites of predilection for esophageal carcinoma. Approximately 50% of cases present clinically in the middle third of the esophagus (constricted by the aortic arch and left main bronchus at the T4 level), while 35% present in the distal third (at the esophageal aperture of the diaphragm).

Two histologic types of esophageal carcinoma are distinguished:

- Squamous cell carcinoma (≥95% of cases, **Fig. 2.31**), which occurs predominantly in the middle and upper thirds of the esophagus.
- Adenocarcinoma (approx. 4% of cases, **Fig. 2.32**), which occurs in the distal esophagus and at the gastroesophageal junction. This tumor is associated with Barrett syndrome (columnar epithelium lining the lower esophagus).

Accurate tumor staging and the determination of histologic tumor type are essential in treatment planning for esophageal carcinoma.

Staging

The extent of esophageal carcinoma is described with the TNM classification, where T indicates the depth of tumor invasion, N describes lymph node status, and M denotes the presence or absence of distant metastasis.

Routes of metastasis. Because the esophagus lacks a serosal covering, esophageal cancer often undergoes early submucous spread at the cervical and thoracic levels. Even early stages show clinical evidence of lymphogenous spread to paraesophageal, mediastinal, cervical, and perigastric regional lymph nodes (stage N1).

Spread to celiac lymph nodes or supraclavicular sentinel nodes is classified as distant metastasis (stage M1).

Esophageal carcinoma undergoes early lymphogenous metastasis.

The CT criteria for a gastric malignancy are circumscribed wall thickening and an intraluminal mass.




Fig. 2.31 a–d Squamous cell carcinoma of the middle third of the esophagus in a 63-year-old man (stage: uT3, N-positive). Follow-up study. CT (a, c) and FDG PET-CT (b, d) before treatment and after completion of the first cycle of neoadjuvant chemotherapy (cisplatin/5-FU). The SUV was reduced from 22.5 (b) to 4.8 (d). Final stage after esophageal resection: ypT0N0.

Imaging studies. Diagnostic imaging during preoperative staging provides a basis for deciding among several treatment options: radical excision with curative intent, neoadjuvant therapy, or a palliative approach. The gold standard for initial diagnosis is endoscopic examination and biopsy. Endoscopy permits a reliable evaluation of the mucosa, but the depth of tumor invasion into the esophageal wall cannot be accurately assessed. This has led to greater reliance on the combined use of esophago-gastroduodenoscopy (EGD) and endosonography, although this method has limited application in patients with strictures and stenoses.

CT. The goal of primary staging is to ascertain the preoperative extent of disease as an aid to planning neoadju-

vant therapy or defining the radiotherapy field. Multislice spiral CT is used for this purpose. This procedure can evaluate possible tumor invasion of adjacent organs (stage T4)—especially the tracheal wall, bronchi, pericardium, and aorta—as well as lymphogenous and hematogenous metastasis. The following CT signs are considered definitive for the invasion of adjacent organs:

- Obliteration of the paraesophageal fat plane
- More than 90° encasement of the aortic circumference
- Airway displacement or compression with intraluminal convexity
- Tracheoesophageal or bronchoesophageal fistula
- Cortical erosion of vertebral bodies

CT is used mainly for the determination of tumor extent.




Fig. 2.32 a–h Adenocarcinoma of the gastroesophageal junction in a 50-year-old man (stage: uT3, N-positive). Follow-up study. CT and FDG PET-CT before treatment (a, b, e, f) and after completion of the first cycle of neoadjuvant chemotherapy (cisplatin/5-FU; c, d, g, h). The SUV was reduced from 17.3 to 3.5. Final stage after esophageal resection: ypT0N0.

Continued →





Fig. 2.32 a–g Continued (see legend on page 122)

Enlargement of paraesophageal or infradiaphragmatic lymph nodes to more than 8 mm is considered evidence of lymphogenous metastasis.

T staging with PET. In several studies, FDG PET has shown a high sensitivity (95%) and specificity (>90%) in the initial evaluation of squamous cell carcinoma and adenocarcinoma of the esophagus (Luketich et al. 1997; Block et al. 1997; Kole et al. 1998; McAteer et al. 1999; Kim et al. 2001; Kato et al. 2002). Most false-negative findings in these studies resulted from very small lesions that were below the 3- to 5-mm spatial resolution limit of PET imaging. No correlation has been found between the intensity of FDG uptake and the depth of tumor invasion in the esophageal wall (Fukunaga et al. 1998; Flamen et al. 2000).

FDG PET and CT have comparable sensitivity in the staging of esophageal cancer (Block et al. 1997; Kim et al. 2001). Due to difficulties in the anatomic correlation of PET findings, however, PET cannot add to the information supplied by endosonography in the assessment of wall invasion.

N staging with PET. The detection of locoregional lymph node metastases (N staging) has considerable prognostic importance. Contrast-enhanced CT is sensitive for this indication but has limited specificity. PET has 100% specificity for the N staging of esophageal carcinoma, but its sensitivity is only 45% (Luketich et al. 1997). The spatial resolution of conventional PET scanners is insufficient to

positively distinguish locoregional lymph node metastasis from primary tumor involvement. Peripheral lymph nodes can be more accurately identified, however.

In recent studies, [^{18}F]FDG PET has been combined with [^{11}C]choline PET to permit the more accurate evaluation of mediastinal lymph nodes. To date, however, this combination has not yielded a diagnostic gain: the sensitivity of [^{18}F]FDG PET was 100% compared with 73% for [^{11}C]choline PET (Jager et al. 2001). This question has not yet been investigated by prospective studies in large groups of patients.

M staging with PET. The detection of distant metastases from esophageal carcinoma (M staging) is a critical factor in determining whether or not surgery is indicated. Patients with nodal or organ metastases have a poor prognosis that would contraindicate a radical excision with its attendant risks and morbidity. In patients with no evidence of distant metastases, the locoregional lymph node status determines the prognosis (Figs. 2.33 and 2.34).

FDG PET has a sensitivity of 69% and a specificity of 93% in the identification of distant metastases (Luketich et al. 1999), compared with only 46% and 74%, respectively, for CT. Even when compared with CT plus endosonography, FDG PET showed a higher sensitivity of 78% (vs. 46%) and a specificity of 90% vs. 69%; Lerut et al. 2000). The additional information supplied by FDG PET over morphologic imaging can influence treatment planning (Chatterton et al. 2009). This prompted the Third German Interdisciplinary Consensus Conference, titled “Onco-Pet III,” to give FDG PET a class 1a indication (es-

FDG PET is superior to CT (even combined with endosonography) in the identification of distant metastases.

Prognosis

Conventional Imaging

Even dynamic contrast-enhanced MRI after preoperative chemotherapy cannot yet give an accurate prediction of lasting tumor remission (Reddick et al. 2001).

FDG PET

With osteosarcoma, the initial FDG uptake of the primary tumor is a prognostic indicator (Franzius et al. 2002b). Intense glucose hypermetabolism is associated with a reduction of overall and disease-free survival. This is consistent with the result of a large study in more than 200 adults and children with bone and soft-tissue sarcomas (Eary et al. 2002).

A prospective study of Ewing tumors demonstrated the prognostic value of glucose metabolism following neoadjuvant chemotherapy. In this study, too, high FDG uptake correlated with a shorter period of disease-free survival (Hawkins et al. 2005).

PET-CT

No studies have yet been published on the prognostic capabilities of PET-CT in patients with primary bone tumors.

Soft-Tissue Sarcomas

Basic Considerations

Soft-tissue sarcomas in children are a heterogeneous group of malignant tumors that originate in the soft tissues and have a predominantly mesenchymal origin. The most common histologic entities in children and adolescents are rhabdomyosarcoma (embryonal and alveolar, 61%), extrasosseous Ewing sarcoma and peripheral neuroectodermal tumor (PNET, 8%), synovial sarcoma, neurofibrosarcoma, fibrosarcoma, and leiomyosarcoma (Kaatsch and Spix 2006). There is no uniform system for the staging and risk grouping of soft-tissue sarcomas. Pretreatment biopsy is always necessary. The diagnosis of soft-tissue sarcoma is based on morphologic and immunohistochemical criteria. The 10-year survival rate is 60% (Kaatsch and Spix 2006).

Conventional Imaging

Ultrasonography is often the initial imaging study for soft-tissue sarcomas, depending on lesion location and accessibility. Other sectional imaging studies are needed for evaluation of tumor extent, however. MRI provides

significantly better soft-tissue contrast, does not involve ionizing radiation exposure, and is therefore preferred over other modalities. Pretreatment staging should also include chest radiographs in two planes, thoracic CT, cranial MRI, and abdominal ultrasonography or MRI (Gadner et al. 2006; AWMF 2007).

PET and PET-CT

No clinical studies have yet been published on the evaluation of pediatric soft-tissue sarcomas with FDG PET and PET-CT. In one series in which PET-CT was used in three patients with rhabdomyosarcoma it was concluded that slight FDG uptake in lymph nodes requires biopsy confirmation as it may indicate either metastasis or nonspecific activity (Ben Arush et al. 2006). In another series of four patients with rhabdomyosarcoma it was concluded that FDG PET is useful for evaluating response to therapy (Peng et al. 2006).

The great majority of soft-tissue sarcomas in children show intense glucose hypermetabolism (Figs. 2.82, 2.83, 2.84, 2.85, 2.86, 2.87). It is reasonable to conclude, then, that FDG PET is clinically useful for staging and for evaluating treatment response. Two larger studies of soft-tissue sarcomas in adults and some children have shown that FDG PET is not useful for the exclusion of pulmonary metastases, analogous to the results with bone sarcomas (Lucas et al. 1998; Iagaru et al. 2006). In cases where PET is proposed for staging, it would definitely be advantageous to obtain simultaneous CT images on a PET-CT scanner (Fig. 2.88)

Neuroblastoma

Basic Considerations

Neuroblastoma is the most common solid extracranial malignant tumor in children. Its incidence is 1.1:100 000 children under 15 years of age (Kaatsch and Spix 2006). As an embryonal tumor, neuroblastoma is most frequently diagnosed in infants and small children. It originates from cells of the neural crest and thus occurs predominantly in the sympathetic trunk, paraganglia, and adrenal medulla. Tumors of the sympathetic nervous system show increased catecholamine production in more than 80% of patients.

Staging is based on the International Neuroblastoma Staging System (INSS). Stage IV, characterized by the presence of distant metastasis, has a particularly grave prognosis. Molecular genetic characteristics also have prognostic significance (e.g., *N-myc* amplification). The 10-year survival rate is 53% for all patients but varies




Fig. 2.82 a–k Ewing tumor. Extraosseous Ewing tumor in the right chest wall of a young male. FDG PET-CT with diagnostic thoracic CT after contrast administration. Tumor has infiltrated all of the right chest wall, the diaphragm, and the mediastinum. Carcinomatous lymphangitis is noted in the right lung.

a FDG PET, coronal whole-body MIP.
b FDG PET, sagittal whole-body MIP.

c–h Axial scans of the chest at two different levels (**c, f** CT with a soft-tissue window; **d, g** FDG PET, **e, h** PET-CT).

i–k Axial scan through the chest (**i** CT with a lung window, **j** FDG PET, **k** PET-CT).




Fig. 2.83 a–k Ewing tumor. Extrasosseous Ewing tumor in the right chest wall of a young male after chemotherapy. FDG PET-CT with diagnostic thoracic CT after contrast administration was performed to evaluate therapeutic response (see initial findings in **Fig. 2.82**). The images document good response with marked regression of metabolic activity and marked size reduction of all lesions.

a FDG PET, coronal whole-body MIP.
b FDG PET, sagittal whole-body MIP.

c–h Axial scans of the chest at two different levels (**c, f** CT with a soft-tissue window; **d, g** FDG PET; **e, h** PET-CT).
i–k Axial scan through the chest (**i** CT with a lung window, **j** FDG-PET, **k** PET-CT).

Index

A

- abdomen, PET interpretation
pitfalls 53–56
- abscess, soft tissue 250
- acetate, ^{11}C - 21
- adenocarcinoma
ampulla of Vater 130
esophagus 120, 121, 125
gastric 126
lung 97–98, 104, 110
- adenoma, colonic 53, 54
- adrenal tumors 155–156, 244
secondary (from lung)
106–108, 108
- Alzheimer disease 271,
272–273, 274, 274–276
- American Academy of Otolaryngology—Head and Neck Surgery, classification of lymph node regions 77
- American Joint Commission (AJCC) staging
bone tumors 196
melanoma 188
renal cell carcinoma 158
testicular germ cell tumors 162
- American Joint Commission (AJCC)/UICC, T staging of head and neck cancer 79
- amino acids as radiotracers 21, 23
- brain tumors 68–69
children 229
differentiation from non-neoplastic lesions 70–71
grading and prognosis 71–72
lymphomas 73
secondary (metastases) 73
treatment response evaluation 72–73
- ammonia, ^{13}N - 22–23
myocardial blood flow 23, 263
- ampulla of Vater, adenocarcinoma 130
- amyloid detection 274
- anaplastic astrocytoma 65
- anaplastic thyroid carcinoma 85, 86, 95
- anesthesia, pediatric 39, 40, 43
- angiography of coronary vessels, CT 266–267
- annihilation 6, 7, 8, 287
- antihormonal therapy, prostatic carcinoma 175
- apoptosis markers 240–241
- approximation methods 5–6
- arm position 34
- arthritis
PET interpretation pitfalls 56
rheumatoid 254, 259
- artifacts 47–49
attenuation-correction 42, 46
brown fat 38, 48, 49, 53
skeletal 57
- astrocytomas 64–65, 73
pediatric 74
- atherosclerosis (and atherosclerotic plaque) 264–265
coronary 262, 266, 269
- attenuation 8, 9, 44–45
coefficients 5, 287
correction 11–12, 46–47
artifacts 42, 46
lymphomas and 186
PET and low-dose CT for
see low-dose CT
- autonomic cardiac innervation 263, 265
- axillary staging, breast cancer 142, 143
- B**
- back-projection 287
CT 4
PET 9
- benign tumors and lesions
artifacts associated with 48
differentiation from malignant
brain 67
female pelvis 145–146
lymphoma 181
melanoma 188–189
musculoskeletal 194
- beta-plus (positron-emitting) particles 15
decay 6–7
- biopsy
brain tumors, planning 72
thyroid cancer 87
- bladder 55
diverticula 54, 55
- blood vessel see vascular system
- bone
[^{18}F]fluoride uptake 21
fractures, PET interpretation pitfalls 56
infection see osteomyelitis
metastases see skeleton
primary tumors 195–201, 245
children 209, 215–222
prognosis 205
recurrence detection 206
response to therapy 205–206
- bone island 197
- bone marrow
infection see osteomyelitis
lymphoma involvement 179
PET interpretation pitfalls 56
- bone scans, children 216, 217, 219
- bowel see intestine
- brain
anatomy 61
degenerative disease 272–280
high-resolution PET 283
brain tumors 61–75, 242
pediatric see children
radiopharmaceuticals 66–74, 239
secondary (metastases) 49, 66, 73
from kidney 160
from lung 108
from unknown primary 232
- breast cancer/carcinoma 140–145
as unknown primary 234
- bronchial carcinoma 31, 47, 98, 99, 100, 106
- bronchio(lo)alveolar carcinoma 98, 100, 111
- brown fat (and artifacts) 48
abdomen 56
chest 53
FDG uptake in children 38
head and neck 49
lymphomas and 180
- C**
- calcifications
coronary artery 266
thyroid cancer 87
- camera design (PET) 9–10
- cancer see tumors
- carbon-11 PET radiotracers 20, 21–22, 23
- carcinoma (major mentions only)
breast see breast cancer
cervical 148–150
cholangiocellular 135
colorectal 53, 54, 138–139, 243
esophageal 120–126
hepatocellular 135
lung 31, 32, 47, 97–113
nasopharyngeal 78, 79, 80, 81
pancreatic 128, 129
prostatic see prostatic carcinoma
renal cell 157–160
small bowel 137
thyroid 85–94, 242
see also adenocarcinoma
carcinoma in situ, ductal 140
carcinomatosis, peritoneal see peritoneal carcinomatosis
cardiovascular disease 261–270
see also heart
carotid artery stenosis 264
cartilaginous tumors 194, 198–201
- catheter, venous 52
- cerebral tumors see brain tumors
- cervical fascia see fascia
- cervical lymph nodes 76, 77
metastases of unknown origin 81, 234
- cervical soft tissues 75
CT (in thyroid cancer) 88
- cervix, cancer 148–150
- chemotherapy
bone marrow activation 56
response evaluation
esophageal carcinoma 125
lung cancer 113
lymphoma 179, 179–180
testicular tumors 164–165
- chest, PET interpretation pitfalls 51–53
- children 37–44, 60, 209–231
advantages of PET-CT 42–43
brain tumors 74, 229–230
amino acid uptake 71
benign–malignant differentiation 67
protocols 37
CT 35, 37
special requirements and problems 37–42
tumors (other than brain) 209–229, 245
- cholangiocellular carcinoma 135
- choline, radiolabeled 22
prostatic carcinoma 172, 172–173, 174, 174–175, 176
- chondrosarcoma 199–201
- coincidence (in CT) 8–9
measurement 7–8
- colitis, ulcerative 256, 257

- colon, PET interpretation pitfalls 53, 54
- color scale 46
- colorectal carcinoma 53, 54, 138–139, 243
- computed tomography (CT) 3–5, 44–45
- adrenal tumors 156
- basic principles 3–5
- bladder cancer 161
- brain tumors 63–66, 67
- children 229
- breast cancer 142
- contrast *see* contrast-enhanced CT; contrast media
- endometrial cancer 151
- esophageal carcinoma 121
- fever of unknown origin 248
- gastric carcinoma 126–127, 127
- head and neck tumors 79–80, 81
- heart 261, 265–267
- coronary disease 261
- hepatoblastoma 228
- images 44–45
- data *see* data
- interpretation/analysis 44–45, 60
- rendering and reconstruction 3–5, 6, 9, 44–45
- inflammatory bowel disease 257
- low-dose *see* low-dose CT
- lung cancer
- non-small cell 99–100, 100–101, 103–104, 106–108, 109
- secondary 116
- lymphoma 181
- melanoma 191
- musculoskeletal tumors 205, 205–206, 206, 243
- bone tumors 195, 196, 216
- children 216
- soft-tissue tumors 201, 201–203
- neurodegenerative disease 272–273
- noncontrast 25
- ovarian cancer 146–147
- pancreatic tumors
- carcinoma 128
- islet cell tumor 131
- pleural mesothelioma 114
- prostatic carcinoma 171
- protocols 34–35
- children 35, 37
- spiral *see* spiral CT
- testicular germ cell tumors 163
- thyroid cancer 87–88
- consent (informed) 33
- children 38
- contrast-enhanced CT 25
- PET-CT with 30, 32
- selective 30, 32
- contrast media 25–30, 59
- brain tumors 63–64
- children 39–40
- head and neck tumors 80
- high concentration, artifacts due to 48
- positive and negative 25–26
- risk/adverse effects 27–28, 28–29
- co-registration, automatic/software-based 3, 30
- coronary arteries (and disease) 261, 262, 263, 264, 266–267, 269
- cost-benefit analysis, melanoma 193
- cost reduction in non-small cell lung cancer 111
- Crohn disease 256, 257, 259
- cyclotron 16–17, 287
- cystic pancreatic tumors 128
- D**
- data
- acquisition (in CT) 3–4, 34
- spiral CT 5, 289
- see also* volume acquisition
- raw (in CT)
- composition 8
- correction 8–9
- dementias 271–272, 272–273, 274–276
- density (CT)
- brain tumor 64
- determination 44–45
- 2-deoxy-2-[¹⁸F]fluoro-D-glucose *see* fluorodeoxyglucose
- 3'-deoxy-3'-[¹⁸F]fluoro-L-thymidine *see* fluorothymidine
- detectors, PET 7
- diaphragmatic motion artifacts 53
- differentiated thyroid carcinoma (DTC) 85, 86
- multimodal treatment and diagnosis 88–93
- diffuse astrocytoma, pediatric 74
- digestive tract *see* gastrointestinal tract
- diverticula, bladder 54, 55
- documentation of PET 47
- L-DOPA, ¹⁸F-labeled analog of 20
- medullary thyroid carcinoma 94
- neurodegenerative disease 273, 277
- pheochromocytoma 156
- dopamine-D₂-receptor antagonist, ¹¹C-labeled 22
- neurodegenerative disease 273–274
- dose (radiation) 288
- and safety considerations 12
- children 40–42
- DOTATOC *see* gallium-67
- DOTATOC
- ductal carcinoma in situ (breast) 140
- duodenum 53
- somatostatinoma 131
- E**
- early detection/diagnosis
- Alzheimer disease 276
- breast cancer 140
- lung cancer (non-small cell) 100–101
- echocardiography 261
- edema (perifocal), brain tumor 64
- education and training 281–282
- effective dose 12, 13
- enchondroma 198
- endocarditis 253, 259
- endocrine gastrointestinal tumors 20, 131–132
- endometrial cancer 150–153
- endoscopy, cervical cancer 148
- see also* mediastinoscopy
- energy dose 12
- enhancement characteristics (CT), brain tumor 64
- Enneking system, bone tumors 196
- enostosis 197
- enteral contrast media 26, 33, 59
- enteroclysis, inflammatory bowel disease 257
- ependymoma 65–66
- epiphysis 57
- esophagus 52
- carcinoma 120–126
- ethmoid sinus tumors, T staging 79
- European Pharmacopoeia, FDG quality control 19
- Ewing sarcoma/tumor 197, 205, 206
- children 216, 217, 220, 221, 222, 223, 245
- examination 30–36
- protocols 30–36, 59–60
- children 27, 35
- technique 34–35
- brain tumor CT 63
- selection 34–35
- exostosis, osteocartilaginous 199
- expiration, mild 35
- extragonadal germ cell syndrome 234, 235
- extravasation of contrast media 27
- eye muscles, PET interpretation pitfalls 49
- F**
- false-negative findings
- head and neck cancer lymph node involvement on CT 80
- lung cancer, FDG PET 100, 111
- false-positive findings 44
- head and neck cancer lymph node involvement on CT 80
- lung cancer, FDG PET 111
- fascia, cervical 75–76
- spaced defined by 76–77
- fasting 33
- children 37
- FDG *see* fluorodeoxyglucose, ¹⁸F- (FDG)
- females (women)
- bladder 160
- breast cancer *see* breast cancer
- genitalia *see* genitalia
- fever of unknown origin 248–249, 259
- fibrillary astrocytoma 64–65
- fibrohistiocytic tumors 201
- field of view (FOV) 10, 45
- FIGO staging
- cervical cancer 148, 149
- endometrial cancer 151
- ovarian cancer 146, 147
- filtered back-projection
- CT 4
- PET 9
- fluoride-18
- in FDG production 17–18
- production 16
- radiopharmaceuticals (other than FDG) containing 20–21, 23
- see also* sodium fluoride
- fluorine-18 (¹⁸F) 6, 7
- fluorodeoxyglucose, ¹⁸F- (FDG) (general aspects only) 15, 17–18, 59
- uptake (general aspects)
- in brown fat in children 38
- focal 51
- mechanisms 17
- weight-adjusted activity in children 39
- see also specific conditions/lesions*

- fluorodihydrotestosterone (FDHT), ¹⁸F-, prostatic carcinoma 172
- 6-fluoro-L-DOPA, ¹⁸F- 20
- brain tumors 69
- O-(2-fluoroethyl)-L-tyrosine (FET), ¹⁸F- 23
- brain tumors 68
- differentiation from non-neoplastic lesions 70
- grading and prognosis 70
- treatment response evaluation 72
- fluoromisonidazole, ¹⁸F- ([¹⁸F] FMISO) 23
- fluorothymidine, ¹⁸F- (and 3'-deoxy-3'-[¹⁸F]fluoro-L-thymidine/FLT) 23, 240
- brain tumors 69
- grading and prognosis 71
- follicular B cell lymphoma 31
- follicular thyroid carcinoma 86
- follow-up examinations
- brain tumors 73
- breast cancer 142
- cervical cancer 148
- lymphoma in children 214
- melanoma 192–193
- prostatic carcinoma 174–175
- see also* recurrence
- FP-TOCA, ¹⁸F-, islet cell tumor 132
- fractures, PET interpretation pitfalls 56
- frontotemporal dementia 272, 273, 276, 278
- fusion images 1
- children
- errors 42
- optimal 42–43
- G**
- gallium-67 DOTATOC
- islet cell tumors 132
- medullary thyroid carcinoma 94
- small bowel carcinoma 137
- gamma radiation 6–7
- personnel safety 13
- gantry aperture size 10–11
- Gardner syndrome 198
- gastric lesions *see* stomach
- gastrinoma 131
- gastroesophageal junction adenocarcinoma 121
- gastrointestinal (digestive) tract contrast media 26, 33, 59
- PET interpretation pitfalls 53
- tumors 53, 54, 120–134, 243
- endocrine 20, 131–132
- lower 137–139, 243
- stromal 131, 132, 137
- upper 120–134, 243
- general anesthesia, pediatric 39, 40, 43
- genitalia
- females
- PET interpretation pitfalls 55
- tumors 145–152, 243–244
- males
- PET interpretation pitfalls 55
- tumors 162–167, 244
- germ cell tumors, male 162, 243
- see also* extragonadal germ cell syndrome
- giant cell arteritis 254, 255
- giant cell tumor of bone 201
- glioblastoma 62–63, 65, 67, 68
- glioma 62–63, 64–65
- malignant progression 62
- gliomatosis cerebri 65
- glucose
- patient levels 33
- see also* fasting
- transporters 17
- grade/grading
- bone tumors 195–196
- brain tumor 71–72
- soft-tissue tumors 201
- graft, vascular, infection 252
- granulomatous inflammations 254
- gray scale 44
- gynecology *see* breast cancer; genitalia
- H**
- half-lives 7, 287
- head and neck 75–84
- anatomy 75–77
- PET interpretation pitfalls 49
- tumors 75–84, 242
- occult (cancer of unknown primary) 81, 234
- radiotherapy *see* radiotherapy
- heart
- CT *see* computed tomography
- endocarditis 253, 259
- failure 269
- global function 267
- see also* coronary arteries; myocardium
- helical CT *see* spiral CT
- hepatocellular carcinoma 135
- heterotopic ossification 205
- high-precision intensity-modulated radiotherapy 241
- high-resolution PET 283, 284
- histiocytic sarcoma 203, 204
- histiocytoma, malignant fibrous 200
- histiocytosis, Langerhans cell 227–228
- Hodgkin disease 177, 178, 179, 180, 181, 184, 185, 243
- pediatric 209–210, 212, 214, 215
- Hounsfield scale/units 5, 287
- Huntington disease 272, 273, 277, 279
- hydroxyephedrine, ¹¹C- ([¹¹C] HED) 23
- pheochromocytoma 156
- 5-hydroxytryptophan (5-HTP), medullary thyroid carcinoma 94
- hypernephroma (renal cell carcinoma) 157–160
- hypopharynx
- anatomy 75
- synovial sarcoma 225
- T staging of tumors 79
- hypoxia markers 82, 240, 241
- I**
- images 44–58, 60
- CT *see* computed tomography
- fusion *see* fusion images
- PET *see* positron emission tomography
- PET-CT, interpretation 47
- implants and prostheses
- joint, infections 251–252
- metal 48, 53, 251
- incidental finding of colorectal carcinoma 139
- indium-111-leukocyte scans, inflammatory diseases 248
- indium-111-octreotide scintigraphy
- pancreatic islet cell tumors 131, 132
- small bowel malignancy 137
- infants, fasting 38
- infections 247, 248–253
- inflammations 247–256
- hypermetabolism 48–49
- in bone 57
- informed consent *see* consent
- injection site, breast cancer PET 144–145
- inspiration depth 35
- insulinoma 131
- interdisciplinary and multidisciplinary teamwork 1
- children 43
- see also* personnel
- intestine (bowel)
- contrast media 26, 33, 59
- inflammatory bowel disease 256–257, 259
- PET interpretation pitfalls 53
- tumors 53, 54, 137–139, 243
- MALT lymphoma 53
- intravascular contrast media
- see* parenteral contrast
- iodinated contrast media 25–26, 26, 27, 28
- iodine-123 scintigraphy
- neuroblastoma 224
- pheochromocytoma 156
- iodine-124 PET tracers 23
- iodine-124 scintigraphy in thyroid cancer, for recurrence detection 93
- iodine-131 scintigraphy in thyroid cancer
- postoperative staging 90
- in suspected recurrence 90, 93
- iodine-131 therapy in thyroid cancer 89
- non-option in medullary carcinoma 93
- islet cell tumors 131–132
- J**
- joints
- PET interpretation pitfalls 56
- prosthetic, infections 251–252
- see also* arthritis
- K**
- kernel 4, 287
- kidney
- cancer 157–160, 243
- children 228, 229
- contrast-induced adverse effects 27–28, 59
- PET interpretation pitfalls 55
- L**
- Langerhans cell histiocytosis 227–228
- large cell carcinoma of lung 102
- large intestine 53
- tumors 138–139, 243
- laryngeal tumors 78
- T staging 79
- legal requirements 13
- leukocyte scans, inflammatory diseases 248
- Lewy body dementia 272, 273, 276
- line of response 8, 287
- lip cancer, T staging 79
- liver 135–136
- metastases 135–136, 243
- from lung 106, 108
- from unknown primary 234–235

- PET interpretation pitfalls 55–56
 primary cancer 135, 243
 hepatoblastoma 228
- low-dose CT
 image analysis 45
 lymphoma 186
 PET and, for attenuation correction 30, 32
 children 41
 PET-CT with 30, 30–32
 whole-body 30, 32
- lung 51–52
 nodules 35, 47, 51, 99, 100, 101
 PET interpretation pitfalls 51–52
- lung cancer 97–113, 242
 non-small cell *see* non-small cell lung
 primary (carcinoma) 31, 32, 47
 radiotherapy *see* radiotherapy
 secondary (metastases) 116–117
 from melanoma 190, 191
 from rhabdomyosarcoma 33
 from unknown primary 232, 234
 small cell 112, 113–116, 242
- lymph nodes 47
 image interpretation 47
 lymphoma involvement 31, 181, 182
 metastases *see* metastases, lymph node; N staging
 neck *see* cervical lymph nodes
 in staging *see* N staging; TNM
- lymphoma 177–187, 209–215, 243
 bowel 53
 cerebral 66, 73, 74
 follicular B cell 31
 gastric 127
 MALT 53, 127
 pediatric 209–215, 245
 thyroid 95
- M**
- M staging (distant metastases in TNM system)
 bone tumors 196, 197
 breast cancer 141, 142
 endometrial cancer 151
 esophageal carcinoma 123–124
 gastric carcinoma 126, 127
 head and neck tumors 78
- lung cancer (non-small cell) 97, 103, 106–109
 melanoma 188, 189–191
 ovarian cancer 147
 pancreatic cancer 128, 129
 prostatic carcinoma 170, 171, 174
 renal cell carcinoma 158, 159
 testicular tumors 162, 163–164
see also metastases, distant
- magnetic resonance imaging (MRI)
 adrenal tumors 156
 bladder cancer 161
 brain tumors in children 229
 cardiac 261
 inflammatory cardiomyopathy 253
 cervical cancer 148
 head and neck tumors 80
 vs PET 81
 hepatoblastoma 228
 inflammatory bowel disease 257
 musculoskeletal tumors 205, 205–206, 206, 243
 bone tumors 195, 196
 soft-tissue tumors 201, 201–203
- magnetic resonance mammography 141–142
- males
 bladder 160
 genitalia *see* genitalia
 prostatic carcinoma *see* prostatic carcinoma
- malignant tumors *see* tumors
- MALT lymphoma 53, 127
- mammography
 conventional (X-ray) 140–141
 in follow-up 142
 MR 141–142
- mass, brain tumor 64
- maxillary sinus tumors, T staging 79
- mediastinum
 endoscopy in lung cancer 104–106
 PET interpretation pitfalls 52
- medullary thyroid carcinoma 85, 86, 93–94
- medulloblastoma 65
 pediatric 65, 74
- melanoma 187–194, 243
 metastases 57–58
- men *see* males
- meningioma 66
- mesenteric lymph node involvement, follicular lymphoma 31
- mesothelioma, pleural 114–116
- metabolic activity (in PET)
 artifacts due to increases or decreases in 48–49
 brain tumors 67
 metaiodobenzylguanidine (MIBG) scintigraphy
 neuroblastoma 224
 pheochromocytoma 156
- metal implants 48, 53, 251
- metastases, distant
 to adrenals 106–108, 108
 from bone, children 216
 cerebral *see* brain
 from cervix 148
 from head and neck cancer 81–82
 from kidney 159, 160
 from liver, screening 135
 in liver *see* liver
 from lung 106–108
 in lung *see* lung
 from melanoma 57–58
 from ovaries 147
 in pancreas 129, 130
 skeletal *see* skeleton
 in small bowel 137
 from thyroid 87–88, 94
 in thyroid 95
 from unknown primary 232–235
see also M staging
- metastases, lymph node
 esophageal cancer, routes 120
 PET interpretation pitfalls 50
 thyroid cancer
 CT 87
 ultrasound 87
 unknown primary 81, 232, 234
see also N staging
- metformin and contrast media 28
- methionine, ¹¹C- (MET) 21
 brain tumors in children 229
 pancreatic cancer 129–131
- MIBG *see* metaiodobenzylguanidine
- monoclonal antibodies, inflammatory diseases 248
- motion artifacts 47
 diaphragmatic 53
 head and neck 49
- mucosa-associated lymphoid tissue (MALT) lymphoma 53, 127
- multidisciplinary teamwork *see* interdisciplinary and multidisciplinary teamwork
- multiphase CT 35
- multiple endocrine neoplasia (MEN) 131
 medullary thyroid carcinoma in 86
 pancreatic tumors 131
- multiple sclerosis 70, 71
- multislice spiral CT 6
 heart 266
- multisystem atrophy 276–277
- muscle activity, PET interpretation pitfalls due to 48, 49, 57
- musculoskeletal system
 infections 249–251, 259
 tumors 194–208, 243
 children 209, 215–222
- myocardium 261
 assessment (viability/function etc.) 23, 261, 262–265
 PET interpretation pitfalls 52
- myositis ossificans 205
- N**
- N staging (nodal involvement in TNM system)
 bone tumors 196, 197
 breast cancer 141, 142
 endometrial cancer 151
 esophageal carcinoma 123, 126
 gastric carcinoma 126, 127
 head and neck tumors
 CT 78, 80
 PET 81
 lung cancer (non-small cell) 97, 98, 99, 103–104
 melanoma 188, 189
 ovarian cancer 147
 pancreatic cancer 128, 129
 prostatic carcinoma 170, 171, 174
 renal cell carcinoma 158, 159
 testicular tumors 162, 163–164
 thyroid cancer 86
see also metastases, lymph node
- nasal cavity tumors 78, 79
- nasopharynx
 anatomy 75
 carcinoma 78, 79, 80, 81
- neck *see* head and neck *and entries under* cervical
- neoadjuvant therapy 288
 in esophageal carcinoma
 chemotherapy 125
 radiotherapy 125
- neoplasms *see* tumors
- nephroblastoma 228, 229
- nephropathy, contrast-induced 27–28, 59
- nerve supply, cardiac 265
- neuroblastoma 209, 221–227
- neurodegenerative disease 272–280
- neurons, presynaptic *see* presynaptic neurons
- nitrogen-13 PET radiotracers 20, 22–23

- nodules
 pulmonary 35, 47, 51, 99, 100, 101
 thyroid 86, 87
- noise equivalent count rate 10
- nonionic contrast media 26
- non-small cell lung cancer 97–109, 242
 radiotherapy planning 238, 239
- O**
- octreotide, ¹¹¹In- *see* indium-111-octreotide scintigraphy
- octreotide analog *see* gallium-67 DOTATOC
- oligoastrocytoma 65
- oncology *see* tumors
- oral cavity
 PET interpretation pitfalls 49
 tumors
 radiotherapy planning 237–238
 T staging 79
- organ dose 12
- oropharynx
 anatomy 75
 T staging of tumors 79
- osseous/osteogenic tumors 194, 197–198
- ossification, heterotopic 205
- osteoblastoma 198
- osteocartilaginous exostosis 199
- osteochondroma 199
- osteoid osteoma 198
- osteoma 198
- osteomyelitis 57, 249–251, 259
 prosthetic joint-associated 251–252
- osteosarcoma 197, 198, 199, 205
 pediatric 215–216, 216, 218, 221, 245
- ovaries 145
 cancer 146–148
 PET interpretation pitfalls 55, 56
- oxygen-15 PET radiotracers 20, 23
- P**
- pancreatic tumors 128–132
- papillary thyroid carcinoma 86
 recurrent 88, 91
- paranasal sinus tumors 78, 79
- parental role 39
- parenteral (incl. intravenous/intravascular) contrast media 26–28, 59
 brain tumors 63–64
- Parkinson disease (and parkinsonism) 272, 273, 276–277, 278
 with dementia 271
- parosteal osteosarcoma 198
- patient
 aperture size 10–11
 preparation 33–34, 59–60
 positioning *see* positioning
 radiation safety 12–13
 selection for radiotherapy 236–239
 table *see* table
 time saving for 43
- pediatrics *see* children
- pelvis, female *see* genitalia
- performance parameters of PET systems 10
- perfusion imaging, myocardial 263–264
- peritoneal carcinomatosis 232
 gastric cancer 127
 ovarian cancer 147
- personnel/staff
 pediatric examination, role 39
 radiation safety 13–14
see also interdisciplinary and multidisciplinary teamwork
- pharynx
 anatomy 75
 tumors 78, 79, 80, 81, 225
 synovial sarcoma 225
- pheochromocytoma 155, 156, 157, 244
- photon absorption 44
- pilocytic astrocytoma 64
 pediatric 74
- pitch (spiral CT) 5, 6, 288
- pleural mesothelioma 114–116
- pneumonia 51–52
- pneumonitis 52
- positioning, patient 3, 34
 brain tumor CT 63
 breast cancer PET 145
 pediatric 42–43
- positron emission tomography/PET (major mentions only) 6–11, 46–58, 288
 adrenal tumors 156
 basic principles 6–11
 bladder cancer 161
 brain tumors 66–74
 children 229
 breast cancer 142–145
 children 37
 cholangiocellular carcinoma 135
 colorectal cancer 138
 esophageal carcinoma 123–124, 124–125, 126
 FDG in *see* fluorodeoxyglucose
- fever of unknown origin 248–249
- gastric carcinoma 127
- head and neck tumors 80–84
- hepatoblastoma 228
- hepatocellular carcinoma 135
- high-resolution 283, 284
- image interpretation 46–47, 60
- pitfalls 47–58
- Langerhans cell histiocytosis 228
- liver cancer 135
- lung cancer
 non-small cell 100, 101–103, 104–106, 108, 109
 secondary 116–117
 small cell 113
- lymphoma 179, 182–186
 pediatric 210, 211, 214, 215
 melanoma 189–190, 191
 musculoskeletal tumors 205, 206
 bone tumors 196, 197, 216, 217–219, 219, 221
 children 216, 217–219, 219, 221
 soft-tissue tumors 201, 203, 221
- myocardial assessment 261, 262–265
- neuroblastoma 224–227
- neurodegenerative disease 273–278
- pancreatic tumors
 carcinoma 129–131
 islet cell tumor 132
- pelvic tumors ♀ 145–146
 endometrial cancer 151–152
 ovarian cancer 146–147
- pleural mesothelioma 114
- prostatic carcinoma 171–175
- renal cell carcinoma 159–160
- testicular tumors 163–167
- thyroid carcinoma 90–93
 medullary 93–94
 unknown primary cancer 233–234, 234
- positron-emitting particles *see* beta-plus particles
- postoperative period in thyroid cancer
 staging 90
- postsynaptic radiopharmaceutical markers 273–274
- presynaptic neurons
 radiopharmaceutical markers 273
- striatal 20
- prognosis
 Alzheimer disease 276
- brain tumors 71–72
- head and neck tumors 82–83
- lung cancer 111–113
- lymphoma 177, 180
 children 214–215
- melanoma 187–188
- metastatic cancer with unknown primary 232
- musculoskeletal tumors 205
- thyroid cancer 93
- projections 288
 CT 3, 4
 algorithms 45
 spiral CT 5
 PET 9, 46
see also back-projection
- proliferation markers 203, 241
- prostatic carcinoma 169–177, 243
 pharmaceuticals 171–175, 239
- prostheses *see* implants and prostheses
- pulmonary tissues/lesions *see* lung
- pyrexia of unknown origin 248–249, 259
- Q**
- quality control, FDG 19
- quantification in PET 46
 brain tumors 68, 69
- R**
- raclopride, ¹¹C- 22
 neurodegenerative disease 273–274
- radiation safety *see* dose; safety considerations
- radiography *see* X-ray radiography
- radioiodine *see* iodine
- radiolabeling 15
- radionuclides (radioisotopes) 6, 7, 20, 288
 production 16–17, 59
 specific, in specific radiotracers 20, 20–21
see also scintigraphy and specific radionuclides
- radiopharmaceuticals (radiotracers) 12, 14–23, 58–59
 administration 33–34
 children 38
 brain tumors 66–74, 239
- inflammatory diseases 247–248
- neurodegenerative disease 273–274
- new/innovative 69, 239–240
- terminology 15–16, 59, 282

- uptake *see* uptake
- radiotherapy 236–242, 282
- brain tumors, planning 72
- esophageal carcinoma, neo-
adjuvant 125
- future outlook 240–241
- head and neck tumors 78
planning 84, 237–238
- lung cancer
assessing response 113
planning 238, 239
- lymphoma, planning 186
- PET interpretation following
48
- planning (in general)
236–242, 246
- random coincidence 8
- reconstruction index 6, 289
- rectal carcinoma 54, 138–139,
243
- recurrence of tumors
colorectal cancer, detection
138–139
- detection and/or staging
brain tumors 73
breast cancer 144
esophageal carcinoma
124–125
gastric carcinoma 127
gynecologic tumors
147–148, 244
head and neck tumors 80
liver metastases 136
lung cancer 109–111
lymphoma in children 214
musculoskeletal tumors
206, 219, 245
pancreatic cancer 129
prostatic carcinoma
174–175
renal cell carcinoma 160
testicular germ cell tumors
165–167
thyroid cancer 87, 88,
90–92
- prognosis, brain tumors 71
see also follow-up
- region of interest (ROI) 34
brain tumors 69
contrast injection and 27
semiautomatic definition 69
- renal cell carcinoma 157–160
see also kidney
- research 282
- retinoblastoma 228–229
- rhabdomyosarcoma 224, 226
pulmonary metastases 33
- rheumatoid arthritis 254, 259
- S**
- safety considerations (incl. ad-
verse reactions)
- contrast media 27–28, 28–29
radiation 12–14, 58
children 40–42
- salivary glands
PET interpretation pitfalls 49
tumors 78, 79
- sarcoidosis 254
- sarcoma
bone 197, 199–201
children 215–222, 245
in small bowel 137
soft-tissue 201, 202, 203,
204, 205
children 221, 224, 225,
226
- scattered coincidence 8, 8–9
- scintigraphy (radionuclide
imaging) 289
bone tumors in children
216, 217, 219
inflammatory diseases 248
fever of unknown origin
248
melanoma 189
neuroblastoma 224
pancreatic islet cell tumors
131, 132
pheochromocytoma 156
thyroid cancer
postoperative 90
recurrence detection and
staging 90, 93
- screening
for breast cancer 140, 142,
143
high-risk women 142
for colorectal cancer 139
for liver cancer metastasis (to
other sites) 135
for liver metastases (from
other sites) 136
- sedation, pediatric 39, 43
- seminomas 163, 164, 165, 166
- sensitivity 289
PET systems 10
- sentinel node scintigraphy,
melanoma 189
- single-phase CT 35
- single photon emission com-
puted tomography (SPECT)
289
myocardial 261
- sinogram 3–4, 289
- skeleton 56–58
image interpretation of
lesions 47
pitfalls in PET 56–58
metastases 56
[¹⁸F] sodium fluoride with
21
image interpretation, and
pitfalls 37, 56
from kidney 160
from lung 108
- from unknown primary
232
see also musculoskeletal
system
- slice
orientation, brain tumors 63
thickness 5, 6, 45, 289
- small cell lung cancer 112,
113–116, 242
- small intestine
cancer 137, 243
PET interpretation pitfalls 53
- sodium acetate *see* acetate
- sodium fluoride (NaF), ¹⁸F- 21
prostatic carcinoma 172, 174,
243
- sodium iodide, ¹²⁴I- 23
- soft tissues
abscess 250
cervical *see* cervical soft
tissues
tumors derived from
201–205, 245
pediatric 209
prognosis 205
recurrence detection 206
response to therapy
205–206
- somatostatin receptor scintig-
raphy *see* indium-111-
octreotide scintigraphy
- sonography *see* ultrasound
- spatial resolution 10
- specific activity of radiophar-
maceuticals 15–16
- spiral CT 5–6, 289
heart 266
pitch 5, 6, 288
- spleen, PET interpretation
pitfalls 55
- squamous cell carcinoma
esophagus 120, 121, 124
head and neck
distant metastases 78, 79
lymph node metastases 82
lung 32, 98, 102, 105, 107
- staff *see* personnel
- staging
bone tumors 196–197, 198,
245
children 216
breast cancer 140, 141, 142,
142–144
esophageal carcinoma
120–124
gastric cancer 126–127
head and neck cancer
CT 78
PET 80–82
lung cancer
non-small cell 97, 100–109
small cell 113
lymphoma 179, 181
pediatric 210–211
- melanoma 188, 189
neuroblastoma 221, 224
pancreatic cancer 128–129
pelvic tumors (females)
145–146, 243–244
cervical cancer 148, 149
endometrial cancer 151
ovarian cancer 146, 147
pleural mesothelioma 114
prostatic carcinoma 170, 171,
173–174
radiotherapy planning and
236
renal cell carcinoma 158, 159
soft-tissue tumors 201–203,
205, 245
testicular tumors 162,
163–164
thyroid cancer 86
postoperative 90
of recurrence 90–91
TNM system *see* TNM staging
system
- stomach
carcinoma 126–127
PET interpretation pitfalls 53
- striatal presynaptic neurons 20
- strip image 4, 289
- stromal tumor, gastrointestinal
(GIST) 131, 132, 137
- surgery
brain tumor 72
testicular tumors 165
thyroid cancer 88–89
postoperative period *see*
postoperative period
- sympathetic cardiac innerva-
tion 263, 265
- synovial sarcoma 225
- T**
- T staging (primary size/extent
in TNM system)
bone tumors 196, 197
breast cancer 141, 142–144
endometrial cancer 151
esophageal carcinoma 123
gastric carcinoma 127, 128
head and neck tumors
CT 78
PET 80–82
lung cancer (non-small cell)
97, 98, 100–103
melanoma 188, 189
ovarian cancer 147
pancreatic cancer 129
prostatic carcinoma 170, 171,
173–174
renal cell carcinoma 158–159
testicular tumors 162, 163
thyroid cancer 86

- table (patient) 11
speed 6
- target volume, radiotherapy 236–239
- teaching/training/education 281–282
- technetium-99m scans
inflammatory diseases 248
thyroid cancer 248
- technical principles 3–13, 58
- technological advances 282–283
- temporal (giant cell) arteritis 254, 255
- tendon attachments 57
- teratoma, testicular 163, 164, 165
- testes
germ cell tumors 162–167, 244
PET interpretation pitfalls 55
- therapy *see* treatment
- thorax (chest), PET interpretation pitfalls 51–53
- 3D volume rendering technique and 3D reconstructions 45
heart 266
- thymus 52–53
- thyroglobulin levels in thyroid cancer, postoperative 90
- thyroid cancer 85–94, 242
- thyroid function, contrast media effects 28
- thyroidectomy 88–89
- L-thyroxine replacement therapy 89
- time-of-flight technology 282, 283, 284
- time saving for patients and doctors 43
- TNM staging system
bone tumors 196
breast cancer 140, 141
endometrial cancer 151
esophageal carcinoma 123–124
gastric carcinoma 126
head and neck cancer 78
lung cancer (non-small cell) 97, 98
melanoma 188
ovarian cancer 147
pancreatic cancer 128–129
prostatic carcinoma 170, 173–174
renal cell carcinoma 158
testicular tumors 162, 163
thyroid cancer 86
see also T; N; M
- tracers *see* radiopharmaceuticals
- training and education 281–282
- treatment (in cancer)
brain tumors *see* brain tumors
breast cancer, response evaluation 144
follow-up *see* follow-up
GI tract tumors
esophageal carcinoma, response evaluation 125, 126
gastric carcinoma, decision making 126
pancreatic cancer, decision making 129
stromal tumors, response evaluation 132
- head and neck cancer, response evaluation 82–83
- lung cancer (non-small cell) individualized 111
response evaluation 113
- lung cancer (small cell) 113
- lymphoma, response evaluation 179, 179–180, 182
children 211
- melanoma 188
response evaluation 192–193
- musculoskeletal tumors, response evaluation 205–206, 245
children 217
- pediatric tumors 209
- pelvic tumors (females), response evaluation 146, 243
- prostatic carcinoma 171
- recurrence following *see* recurrence
- renal cell carcinoma, response evaluation 159
- response evaluation (in general) 240
- testicular tumors, response evaluation 164–165
- thyroid cancer, multimodal 88–93
see also specific tumor sites and modes of therapy
- tumor(s)/neoplasms (incl. malignant tumors/cancer and oncology) 1, 61–246
adrenal *see* adrenal tumors
artifacts associated with
benign tumors 48
hypometabolic tumors 47–48
- brain *see* brain tumors
FDG metabolism in 17
- gastrointestinal *see* gastrointestinal tract
- genitalia *see* genitalia
- head and neck *see* head and neck
- liver *see* liver
- lymphoid 177–187
- musculoskeletal *see* musculoskeletal system
- pancreatic 128–132
- pediatric *see* children
- prostatic *see* prostatic carcinoma
- radiopharmaceuticals used with 20, 21, 22
- respiratory tract (lower) *see* lung cancer; pleural mesothelioma
- secondary *see* metastases
- skin *see* melanoma
- testicular (germ cell) 162–167, 243
- thyroid 85–94, 242
- treatment *see* treatment
- unknown primary 81, 222–225, 246
- urinary tract 157–161, 243
see also specific types
- tumor markers
cervical cancer 148
germ cell tumors (males) 162
prostatic carcinoma 170, 172
- tunnel length 11
- U**
- ulcerative colitis 256, 257
- ultrasound
breast cancer 141
in follow-up 142
cervical cancer 148
ovarian cancer 146
testicular cancer 163
thyroid cancer 86–87
postoperative staging 90
for suspected recurrence 90, 93
see also echocardiography
- undifferentiated tumors *see* entries under anaplastic
- unknown origin
cancer of 81, 222–225, 246
fever of 248–249, 259
- uptake (radiotracer)
[¹⁸F]FDG *see* fluorodeoxyglucose
quantification 35–36, 60
skeletal 56–57
time 34
- ureter, PET interpretation pitfalls 50, 55
- urinary tract
cancer 157–161, 243
PET interpretation pitfalls 55
see also specific regions/parts
- uterus 145
PET interpretation pitfalls 55
- V**
- vascular dementias 272
- vascular system
graft infection 252
inflammation (vasculitis) 254–256, 259
pancreatic cancer involving 128
- Vater's ampulla, adenocarcinoma 130
- venous catheter 52
- volume acquisition 5, 289
spiral CT 6
- W**
- water, ¹⁵O- 23
myocardial perfusion assessment 23, 263
- WHO *see* World Health Organization
- whole-body PET-CT with low-dose CT 30, 32
- Wilms' tumors 228, 229
- women *see* females
- World Health Organization classification
brain tumors 61, 62–63
lymphomas 178
musculoskeletal tumors 194
- wound healing 48
- X**
- X-ray, personnel safety 13
- X-ray radiography
bone tumors 195
breast (mammography) 140–141
chest (cervical cancer metastases) 148
inflammatory bowel disease 257
- 5-hydroxytryptophan (5-HTP), medullary thyroid carcinoma 94